Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor.

OBJECTIVE Improved predictive imaging would enable personalization and adjustment of treatment, which are critical for patients with glioblastomain whom therapy is likely to fail. This article describes the use of MR spectroscopic imaging (MRSI) to predict early clinical and behavioral response to a therapy and an effort to develop high-resolution, volumetric MRSI to improve its clinical application. CONCLUSION MRSI may enable quantitative analysis of brain tumor response, offering a precise tool for monitoring of patients in clinical trials.

[1]  J. Pruim,et al.  Contribution of magnetic resonance spectroscopic imaging and L-[1-11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy. , 1994, Neurosurgery.

[2]  M. Maio,et al.  Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications , 2007, Journal of cellular physiology.

[3]  T R Brown,et al.  Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. , 1996, Journal of neurosurgery.

[4]  Timothy A. Chan,et al.  MRI perfusion in determining pseudoprogression in patients with glioblastoma. , 2013, Clinical imaging.

[5]  C. Nimsky,et al.  Proton Magnetic Resonance Spectroscopic Imaging in the Border Zone of Gliomas: Correlation of Metabolic and Histological Changes at Low Tumor Infiltration—Initial Results , 2007, Investigative radiology.

[6]  M. Martel,et al.  Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. , 1999, International journal of radiation oncology, biology, physics.

[7]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[8]  Abass Alavi,et al.  Positron emission tomography in patients with glioma a predictor of prognosis , 1988, Cancer.

[9]  A. Lehninger.  Principles of Biochemistry , 1984 .

[10]  J. Olson,et al.  Magnetic resonance spectroscopic imaging in the era of pseudoprogression and pseudoresponse in glioblastoma patient management. , 2013, CNS oncology.

[11]  David A Mankoff,et al.  Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  J. Boyle.  Lehninger principles of biochemistry (4th ed.): Nelson, D., and Cox, M. , 2005 .

[13]  M. J. van den Bent,et al.  Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.

[14]  J K Smith,et al.  Correlation of myo-inositol levels and grading of cerebral astrocytomas. , 2000, AJNR. American journal of neuroradiology.

[15]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[16]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[17]  Varan Govind,et al.  Erratum: Impact of reduced k-space acquisition on pathologic detectability for volumetric MR spectroscopic imaging (Journal of Magnetic Resonance Imaging (2014) 39 (224-234)) , 2014 .

[18]  J Hennig,et al.  Human brain tumors: assessment with in vivo proton MR spectroscopy. , 1993, Radiology.

[19]  O. Ganslandt,et al.  Magnetic Resonance Spectroscopic Imaging for Visualization of the Infiltration Zone of Glioma , 2010, Central European neurosurgery.

[20]  Emma Y. Wu,et al.  Antidepressant Actions of Histone Deacetylase Inhibitors , 2009, The Journal of Neuroscience.

[21]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[22]  A. Carson,et al.  Depression in cerebral glioma patients: a systematic review of observational studies. , 2011, Journal of the National Cancer Institute.

[23]  Geon-Ho Jahng,et al.  True Progression versus Pseudoprogression in the Treatment of Glioblastomas: A Comparison Study of Normalized Cerebral Blood Volume and Apparent Diffusion Coefficient by Histogram Analysis , 2013, Korean journal of radiology.

[24]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[25]  A G Sorensen,et al.  Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma , 2011, American Journal of Neuroradiology.

[26]  J. Jääskeläinen,et al.  Debulking or biopsy of malignant glioma in elderly people – a randomised study , 2003, Acta Neurochirurgica.

[27]  Scott N. Hwang,et al.  Early prediction of response to Vorinostat in an orthotopic rat glioma model , 2012, NMR in biomedicine.

[28]  J. G. Salway,et al.  Metabolism at a glance , 1993 .

[29]  Tae Min Kim,et al.  Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. , 2013, Radiology.

[30]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[31]  Tae Min Kim,et al.  Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas. , 2012, Academic radiology.

[32]  H. Lanfermann,et al.  Myo‐Inositol: a marker of reactive astrogliosis in glial tumors? , 2008, NMR in biomedicine.

[33]  Charles L. Raison,et al.  Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression , 2009, Biological Psychiatry.

[34]  C. Dinarello,et al.  Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer , 2011, Molecular medicine.

[35]  Benedick A Fraass,et al.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Ilwoo Park,et al.  Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. , 2007, International journal of radiation oncology, biology, physics.

[37]  A. Rush,et al.  The inventory for depressive symptomatology (IDS): Preliminary findings , 1986, Psychiatry Research.

[38]  Ewald Moser,et al.  Improved delineation of brain tumors: an automated method for segmentation based on pathologic changes of 1H-MRSI metabolites in gliomas , 2004, NeuroImage.

[39]  G Friedmann,et al.  Human brain tumors: spectral patterns detected with localized H-1 MR spectroscopy. , 1992, Radiology.

[40]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  J. Pouliot,et al.  The need for application-based adaptation of deformable image registration. , 2012, Medical physics.

[42]  M. Grunstein,et al.  Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3 , 1998, Nature.

[43]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[44]  K. Wallner,et al.  Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. , 1989, International journal of radiation oncology, biology, physics.

[45]  L O Hall,et al.  Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging , 2006, NMR in biomedicine.

[46]  Mohammad Sabati,et al.  Impact of reduced k‐space acquisition on pathologic detectability for volumetric MR spectroscopic imaging , 2014, Journal of magnetic resonance imaging : JMRI.

[47]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.